NDASUBLINGUALTABLET
Approved
Aug 2009
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Data completeness
5/8 — Partial
SAPHRIS (asenapine maleate) by AbbVie is asenapine, in schizophrenia and bipolar i disorder, is unknown. Approved for schizophrenia. First approved in 2009.
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SAPHRIS (asenapine maleate) is a small-molecule atypical antipsychotic approved by the FDA in August 2009 for the treatment of schizophrenia. Administered sublingually as a tablet, asenapine is believed to exert its therapeutic effects through antagonism at dopamine D2 and serotonin 5-HT2A receptors, though the exact mechanism in schizophrenia and bipolar disorder remains incompletely understood. The sublingual formulation offers a unique delivery route among antipsychotics, potentially improving medication adherence through rapid onset of action.
$0.0BPart D
5mo to LOEMechanism of Action
asenapine, in schizophrenia and bipolar I disorder, is unknown. It has been suggested that the efficacy of asenapine in schizophrenia could be mediated through a combination of antagonist activity at D 2 and 5-HT 2A receptors.
Indications (1)
Why This Matters for Your Career
Worked on SAPHRIS at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.